|Losartan||Angiotensin II receptor antagonist|
|Trade names||Anzaplus, Cozaar comp, Hyzaar, Ocsaar Plus|
|ATC code||C09DA01 (WHO)|
The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden and South Africa.
In 2010, the patent for the combination expired, and a number of pharmaceutical companies promptly filed and received approval to sell the generic losartan, with and without hydrochlorothiazide, in the United States.
The recommended dosage of losartan-hydrochlorothiazide for adults with high blood pressure (hypertension) will vary between losartan-hydrochlorothiazide 50 mg/12.5 mg and losartan-hydrochlorothiazide 100 mg/25 mg once a day. Based on the initial blood pressure response and/or losartan-hydrochlorothiazide side effects, the dosage may be increased or decreased. With each change in dosage, it may take up to a month to see the full effect of losartan-hydrochlorothiazide on lowering blood pressure.
- http://web.archive.org/web/20100429175034/http://www.marketwatch.com:80/story/teva-announces-final-approval-of-generic-hyzaarr-and-cozaarr-2010-04-07. Archived from the original on April 29, 2010. Retrieved April 20, 2011. Missing or empty
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|